Medicortex Finland Oy

Medicortex Finland Oy Announces Issuance of a Patent in Canada

Share

TURKU, Finland. Medicortex Finland Oy, a biopharmaceutical company focusing on the development of diagnostics and drug treatment for mild traumatic brain injury (TBI), today announced that company’s core patent covering the diagnostic kit and innovative biomarker was granted in Canada.

“This is a big achievement - we are very pleased with the development of our patent portfolio” said Doctor Adrian Harel, Chief Executive Officer of Medicortex. “This new issuance continues to increase the intellectual property portfolio covering methods of using certain biomarkers for detection of concussion and mild TBI. The issuance of this patent is another important step in the development of a robust patent portfolio relating to new strategy to help identify and treat mild TBI” Dr. Harel continued with great pleasure.

Medicortex is currently developing a rapid diagnostic kit for detection of concussion and mild traumatic brain injury from urine or saliva. The kit is based on specific biomarkers that the company has discovered from body fluids following brain injury. Such a rapid kit will satisfy the urgent need to improve the detection of brain injury in mild cases especially – which are known to be potentially morbid but difficult to diagnose with the contemporary means. The issued patent covers the core technology and method for detecting glycan-based biomarkers which are indicative of traumatic brain injury.

The issued Canadian patent number 2,982,503 “Prognostic and Diagnostic Glycan-Based Biomarkers of Brain Damage” is the third grant in the patent family where relative patents were previously issued in Europe and in the USA. Canada is an important region to get the biomarker technology protected as there are several hundreds of thousands brain injury cases in the country every year and the incidence is high because of national sports such as ice hockey and other winter games.

Medicortex’ patent portfolio encompasses diagnostics of TBI biomarkers as well as related drug candidates developed by the company. The comprehensive patent coverage secures exclusivity to develop the products and the company’s strategy is to actively seek new patentable innovations from its biomarker and drug development programs.

As Medicortex reached this important milestone, preparations are underway for an Initial Public Offering and a listing of the company’s shares on a stock exchange. Medicortex is currently performing a financing round (pre-IPO) which will equip Medicortex with the necessary resources to ambitiously further develop and strengthen the company for its planned IPO. To read more about the investment case, please visit the Medicortex website (www.medicortex.fi/investors).


Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Medicortex assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Keywords

Contacts

Medicortex Finland Oy
Dr. Adrian Harel - CEO
Tel. +358 (0) 400 488 817
adrian.harel@medicortex.fi
http://www.medicortex.fi

About Medicortex Finland Oy

Medicortex Finland Oy
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B
20520 TURKU

http://www.medicortex.fi

Medicortex Finland Oy is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect head injury. The company has the technology to capture biomarkers from urine and saliva and to develop them into an affordable diagnostic tool. Medicortex was established by an Israeli neurobiologists Adrian Harel (PhD, MBA) in 2014, and the company is based in Turku, Finland.

Subscribe to releases from Medicortex Finland Oy

Subscribe to all the latest releases from Medicortex Finland Oy by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Medicortex Finland Oy

Medicortex Finland Oy Announces the Advancement in Clinical Trial for Detection of Mild Traumatic Brain Injury in Children31.8.2020 15:43:39 EEST | Press release

TURKU, Finland. Medicortex Finland Oy announces achievement of the halfway in the clinical trial for detection of mild traumatic brain injury (TBI) and concussion in children and adolescents. Company's third clinical trial is being conducted at Satasairaala hospital in Finland. About 50% of the target number of head injury patients and healthy controls have already been enrolled in the study which started in March this year.

Medicortex Finland Oy Announces the Progression of Clinical Trial for Detection of Mild Traumatic Brain Injury in Children9.6.2020 12:15:42 EEST | Press release

TURKU, Finland. Medicortex Finland Oy announces the progression of clinical trial for detection of mild Traumatic Brain Injury (TBI) and concussion. Company’s third clinical trial is focusing on children and adolescents, and the recruitment of patients is taking place at Satasairaala hospital in Finland. The first patients with head injury and the first healthy controls have been enrolled in the study.

Medicortex Finland Oy:lle tutkimusrahoitusta Yhdysvaltain Puolustusministeriöltä3.7.2019 14:00:00 EEST | Tiedote

Turku, 03.07.2019. Medicortex Finland Oy:lle on myönnetty Yhdysvaltain puolustusministeriön 1,1 miljoonan dollarin tutkimusrahoitus. Rahoituksen avulla yhtiö jatkaa ProbTBITM -aivovammatestin kliinistä kehitystyötä. Tämä vahvasti kilpailtu rahoitus on samalla myös tunnustus Medicortexin teknologian ja tuotteen kyvylle vastata kasvavaan tarpeeseen määrittää tapaturmainen aivovamma tai aivotärähdys nopeasti ja luotettavasti.